Skip to main content
. 2022 Jul 20;108(2):123–130. doi: 10.1136/archdischild-2022-324375

Figure 4.

Figure 4

Summary of symptoms reported by participants seropositive on RocheS (anti-SARS-CoV-2 IgG spike protein antibodies) by age group.